Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens

... The compounds are expected to be devoid of systemic activity and will be developed for skin and hair ... The lead compound, HYG-440, is expected to lack systemic effects. The addition of the series of ... topical drugs are expected to have negligible systemic effects and have a better safety profile than ...

Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply

... fifth birthday). The most common local and systemic adverse reactions to Pentacel vaccine include ... crying. Other adverse reactions may occur. Known systemic hypersensitivity reaction to any component of ... type b disease. The most common local and systemic adverse reactions to ActHIB vaccine include ...

Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections

... antibiotics are often associated with systemic side effects and widespread use can lead to ... drug at the target tissue, while maintaining low systemic levels well below the toxicity threshold. The ... is investigating the product as an adjunct to systemic antibiotic therapy for treating moderately ...

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

... of care in patients with serologically active systemic lupus erythematosus (SLE). The results were ... commercialized under the agreement. About systemic Lupus Erythematosus systemic lupus erythematosus (SLE) is a chronic, ...

First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease

... which are burdened with a variety of serious systemic side effects when given orally. Even if applied ... this recommendation. It is well documented that systemic steroids at doses above 10 mg/day cause a myriad ... chronic corticosteroid use. "The tapering of systemic corticosteroids to 5 mg or less per day, as ...

Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence

... Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today ... discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the ... in its potential to offer safe and effective systemic administration using a library of novel ...

Intradigm Closes Final Tranche of $21.4 Million Series B Financing

... Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, ... technology, toward the development of systemic siRNA therapeutic candidates with an initial ... discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the ...

Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery

... urinary stones, and was designed to evaluate the systemic absorption and safety of the drug product. The pharmacokinetic data from this study show that systemic plasma levels of the active agents of OMS201 in ... parallel-assigned study designed to evaluate the systemic absorption and safety of OMS201 in patients ...

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics

... Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, ... discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the ... in its potential to offer safe and effective systemic administration using a library of novel ...

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

... potential solutions for patients struggling with systemic autoimmune rheumatic diseases," said ... conducting a phase 2a trial in patients with systemic lupus erythematosus (SLE) and a phase 1b ... -- IFN-alpha/beta as a therapeutic target in systemic lupus erythematosus, myositis, and ...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

... rearrangements; adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-KIT ... to be reversible with the administration of systemic steroids, circulatory support measures, and temporarily withholding imatinib. MDS/MPD disease and systemic mastocytosis may be associated with high ...

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

... siRNA molecules in vitro and in vivo, as well as systemic siRNA delivery systems. These include AtuPLEX, Silence's proprietary systemic delivery system that enables the functional ... addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables ...

Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments

... in second LymphoStat-B(R) Phase 3 trial in systemic lupus erythematosus; completion of randomization ... in chronic hepatitis C and LymphoStat-B(R) in systemic lupus erythematosus," said H. Thomas ... Screening Completed in Second Phase 3 Trial in systemic Lupus Erythematosus; Timeline on Track for Phase ...

Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027

... active drug into the appropriate cells following systemic administration. "The protection of targets ... addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables ... AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully ...

Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference

... of temporarily inhibiting p53 as a systemic therapy to prevent the development of acute ... I clinical trials and represents the first ever systemic dosing of an siRNA in humans. Dr. Swetlana ... currently in Phase I/IIa clinical trials via systemic delivery. Based on publicly ...

Oncolytics Biotech Inc. Announces 2008 First Quarter Results

... responses to REOLYSIN(R) in our U.K. Phase I systemic administration trial was published in the ... or fallopian tube cancers using concurrent systemic and intraperitoneal administration of ... trials of the use of cyclophosphamide prior to systemic reovirus administration to modulate, but not ...

Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School

... Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today ... known as PolyTran(TM). PolyTran enables safe systemic delivery of the siRNAs. Additionally, this ... company dedicated to the development of targeted, systemic RNA interference (RNAi) therapeutics for the ...

Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure

... of the study, a prespecified reduction in systemic blood pressure. No volunteer experienced a ... for the emergency treatment of severe acute systemic hypertension. A Phase IIa study in hypertensive ... for CHF were $29.6 billion in 2006. About Acute systemic Hypertension An acute elevation of blood ...

Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial

... the lymphatic circulation and ultimately, the systemic circulation. Designed to exert its effect only in ... barrier through which to drive compounds into the systemic circulation - that is, as an obstacle to be ... eliminates the major stumbling block of systemic bioavailability encountered by other ...

REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide

... plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. In ... a contraindication to, or are intolerant of other systemic therapy including cyclosporine, methotrexate or ...

Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases

... liver and fat, thereby potentially minimizing the systemic side effects that would be expected ... Type 2 diabetes, the side effects associated with systemic GCCR inhibition have challenged development ... GCCR expression in these two organs can lead to systemic side effects. In preclinical studies, Isis has ...

Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria

... where it demonstrated sustained release in the lung with minimal systemic exposure." About ARIKACE(TM) ARIKACE is a ... technology prolongs the release of amikacin in the lungs while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung ...

Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients

... in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to ... while a diagnostic workup is performed for patients who develop a serious systemic illness and reside or travel in regions where mycoses are endemic. ...

Phosphagenics Announces Completion of Transdermal Patch Prototypes

... should increase the amount and duration of oxycodone delivered into the systemic circulation, and could reduce potential opioid abuse, a major ... as well as other products that are targeted for delivery into the systemic circulation, including insulin. Phosphagenics has already completed a ...

Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver

... the formation of its active triphosphate in the liver, while minimizing systemic exposure to IDX184 and the resulting nucleoside metabolite (NM). IDX184 is ... and the nucleoside metabolite were consistent with a liver-targeted drug. systemic exposures and plasma half-life of the nucleoside metabolite were similar ...

BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma

... the study were progressing after having failed prior therapy. 13 objective systemic responses (26% objective response rate) were achieved including eight CRs, ... the lack of any efficacious drugs for metastatic disease. Current systemic therapies are not generally effective in terms of generating durable ...

Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008

... patient enrolment in five new trials: - NCI-sponsored Phase I/II systemic and peritoneal administration trial in patients with ovarian, ... and fallopian tube cancers; - NCI-sponsored Phase II systemic administration trial in patients with metastatic melanoma; ...

Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors

... photodynamic therapy generated direct local cytotoxicity and induced a systemic immune response, which could enhance its therapeutic effect on both ... therapy, potentially making immunophotodynamic therapy a superior systemic cancer treatment modality," said Thomas Woo, Vice President of Product ...

Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics

... severe disease cases they frequently require periocular injections or even systemic immunosuppressive therapy. In contrast, in preclinical in vivo testing, ... high drug concentrations to targeted sites, coupled with strikingly low systemic load and the resulting lowered risk of drug interactions, puts it at the ...

Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery

... with simultaneous opioid sparing effect, all without adding to the systemic side- effects commonly seen with opioids. These results suggest that Adlea ... in the blood after 24 hours. Adlea's short duration of systemic exposure (hours) relative to the long duration of analgesia may offer a ...

Oncolytics Biotech Inc. Announces 2008 Third Quarter Results

... of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel ... a Phase II clinical trial for patients with metastatic melanoma using systemic administration of REOLYSIN(R); - The start of patient enrolment ...

ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting

... inflammatory process, relieves both inflammation of the joints and certain systemic effects of RA. The extensive clinical development program conducted by ... About Rheumatoid Arthritis Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in ...

Cardica Receives $1 Million Milestone Payment From Cook Medical for Development of Heart Defect Closure Device

... risk for several serious medical conditions, including stroke and systemic embolism, because blood clots can pass directly through the hole and into ... with PFO often are asymptomatic, but they are at greater risk for stroke, systemic embolism and debilitating migraine headaches because routine blood clots ...

ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications

... fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. Current venture ...

Silence Therapeutics Patent Update

... nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of ... Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat ...

Organizational Changes at Silence Therapeutics

... nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of ... Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat ...

Silence Therapeutics Announces Successful Opposition of Glover Patent

... nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of ... Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat ...

FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions

... or call 1-888.84.BAYER. WARNING: NEPHROGENIC systemic FIBROSIS Gadolinium-based contrast agents increase the risk of ... magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all ...

FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry

... nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of ... Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat ...

AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy

... exon-skipping snRNA program Bozzoni and co-workers demonstrated long term systemic and therapeutic effect in animals after a single administration[1]. One of the important advantages of the Bozzoni technology is that a single systemic delivery of the AAV vector containing the required antisense RNA-coding ...